Ototoxic effects of mefloquine in cochlear organotypic cultures

Journal of Otology

Volumn 4, Issue 2, 2009, Pages 76-85

  Ding, Da–lian ^a,c,d   Wei–dong, Qi ^a,b   Dong–zhen, Yu ^a,c   Hai–yan, Jiang ^a   Salvi, Richard ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

axon degeneration; inner hair cell; Mefloquine; neurons; Neuropathology; Ototoxicity; outer hair cell; spiral ganglion

Indexed keywords

EID: 84969300514     PISSN: None     EISSN: 16722930     Source Type: Journal    
DOI: 10.1016/S1672-2930(09)50018-9     Document Type: Article

References (51)

1. Sogunro, R., Malaria. Sante Salud, 5–6, 1993.
2. Crawley, J., Nahlen, B., Prevention and treatment of malaria in young African children. Semin Pediatr Infect Dis 15 (2004), 169–180.
3. Snow, R.W., Guerra, C.A., Mutheu, J.J., et al. International funding for malaria control in relation to populations at risk of stable Plasmodium falciparum transmission. PLoS Med, 5, 2008, e142.
4. Schwartz, E., Potasman, I., Rotenberg, M., et al. Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 65 (2001), 189–192.
5. Kollaritsch, H., Karbwang, J., Wiedermann, G., et al. Mefloquine concentration profiles during prophylactic dose regimens. Wien Klin Wochenschr 112 (2000), 441–447.
6. Simpson, J.A., Price, R., ter Kuile, F., et al. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther 66 (1999), 472–484.
7. Phillips–Howard, P.A., ter Kuile, F.O., CNS adverse events associated with antimalarial agents. Fact or fiction?. Drug Saf 12 (1995), 370–383.
8. Muentener, P., Schlagenhauf, P., Steffen, R., Imported malaria (1985–95): trends and perspectives. Bull World Health Organ 77 (1999), 560–566.
9. Dow, G.B.R., Caridha, D., Cabezas, M., et al. Mefloquine ind– uces dose–related neurological effects in a rat model. Antimicrobial Agents and Chemotherapy 50 (2006), 1045–1053.
10. Rendi–Wagner, P., Noedl, H., Wernsdorfer, W.H., et al. Unex–pected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop 81 (2002), 167–173.
11. Barrett, P.J., Emmins, P.D., Clarke, P.D., et al. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. Bmj 313 (1996), 525–528.
12. Croft, A.M., World, M.J., Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet, 347, 1996, 326.
13. Hennequin, C., Bouree, P., Bazin, N., et al. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Intern Med 154 (1994), 2360–2362.
14. Pous, E., Gascon, J., Obach, J., et al. Mefloquine–induced grand mal seizure during malaria chemoprophylaxis in a non–epileptic subject. Trans R Soc Trop Med Hyg, 89, 1995, 434.
15. Sturchler, D., Handschin, J., Kaiser, D., et al. Neuropsychiatric side effects of mefloquine. N Engl J Med 322 (1990), 1752–1753.
16. Weinke, T., Trautmann, M., Held, T., et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 45 (1991), 86–91.
17. Schlagenhauf, P., Mefloquine for malaria chemoprophylaxis 1992–1998: a review. J Travel, Med 6 (1999), 122–133.
18. Fusetti, M., Eibenstein, A., Corridore, V., et al. Mefloquine and ototoxicity: a report of 3 cases. Clin Ter 150 (1999), 379–382.
19. Ding, D., Stracher, A., Salvi, R.J., Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity. Hear Res 164 (2002), 115–126.
20. Zhang, M., Liu, W., Ding, D., et al. Pifithrin–alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin–induced apoptosis. Neuroscience 120 (2003), 191–205.
21. Ding, D., Jiang, H., Wang, P., et al. Cell death after co–administration of cisplatin and ethacrynic acid. Hear Res 226 (2007), 129–139.
22. Amstad, P.A., Yu, G., Johnson, G.L., et al. Detection of caspase activation in situ by fluorochrome–labeled caspase inhibitors. Biotechniques 31 (2001), 608–610 612, 614, passim.
23. Ding, D., McFadden, S.L., Salvi, R.J., Cochlear hair cell densities and inner ear staining techniques. Willott, J., (eds.) The auditory psychobiology of the mouse, 2001, CRC Press, Boca Raton, 189–204.
24. Dow, G.S., Koenig, M.L., Wolf, L., et al. The antimalarial potential of 4–quinolinecarbinolamines may be limited due to neurotoxicity and cross–resistance in mefloquine–resistant Plasmodium falciparum strains. Antimicrob Agents Chem– other 48 (2004), 2624–2632.
25. Toovey, S., Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis 7 (2009), 2–6.
26. Crofton, K.M., Dean, K.F., Menache, M.G., et al. Trimethyltin effects on auditory function and cochlear morphology. Toxicol Appl Pharmacol 105 (1990), 123–132.
27. Stebbins, W.C., Moody, D.B., Hawkins, J.E., et al. The species–specific nature of the ototoxicity of dihydrostreptomycin in the patas monkey. Neurotoxicology 8 (1987), 33–44.
28. Hashino, E., TinHan, E.K., Salvi, R.J., Base–to–apex gradient of cell proliferation in the chick cochlea following kanamycin–induced hair cell loss. Hear Res 88 (1995), 156–168.
29. Sha, S.H., Taylor, R., Forge, A., Schacht, J., Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res 155 (2001), 1–8.
30. Park, B.C., Park, S.H., Paek, S.H., et al. Chloroquine–induced nitric oxide increase and cell death is dependent on cellular GSH depletion in A172 human glioblastoma cells. Toxicol Lett 178 (2008), 52–60.
31. Meng, X.W., Feller, J.M., Ziegler, J.B., et al. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum 40 (1997), 927–935.
32. Zhou, H.J., Wang, W.Q., Wu, G.D., et al. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol 47 (2007), 131–138.
33. Nilkaeo, A., Bhuvanath, S., Praputbut, S., et al. Induction of cell cycle arrest and apoptosis in JAR trophoblast by antimalarial drugs. Biomed Res 27 (2006), 131–137.
34. Totino, P.R., Daniel–Ribeiro, C.T., Ferreira–da–Cruz, Mde F., Pro–apoptotic effects of antimalarial drugs do not affect mature human erythrocytes. Acta Trop 112 (2009), 236–238.
35. Takano, J., Tomioka, M., Tsubuki, S., et al. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J Biol Chem 280 (2005), 16175–16184.
36. Regan, R.F., Panter, S.S., Witz, A., et al. Ultrastructure of excitotoxic neuronal death in murine cortical culture. Brain Res 705 (1995), 188–198.
37. Cotter, T.G., Lennon, S.V., Glynn, J.G., et al. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res 10 (1990), 1153–1159.
38. Siegmund, D., Mauri, D., Peters, N., et al. Fas–associated death domain protein (FADD) and caspase–8 mediate up–regulation of c–Fos by Fas ligand and tumor necrosis factor–related apoptosis–inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP) –regulated pathway. J Biol Chem 276 (2001), 32585–32590.
39. Zhang, X., Vallabhaneni, R., Loughran, P.A., et al. Changes in FADD levels, distribution, and phosphorylation in TNFalpha–induced apoptosis in hepatocytes is caspase–3, caspase–8 and BID dependent. Apoptosis 13 (2008), 983–992.
40. Sprick, M.R., Weigand, M.A., Rieser, E., et al. FADD/MORT1 and caspase–8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12 (2000), 599–609.
41. Iordanov, M.S., Kirsch, J.D., Ryabinina, O.P., et al. Recruitment of TRADD, FADD, and caspase 8 to double–stranded RNA–triggered death inducing signaling complexes(dsRNA–DISCs). Apoptosis 10 (2005), 167–176.
42. Cunningham, L.L., Matsui, J.I., Warchol, M.E., et al. Overexpression of Bcl–2 prevents neomycin–induced hair cell death and caspase–9 activation in the adult mouse utricle in vitro. J Neurobiol 60 (2004), 89–100.
43. Johnson, C.R., Jarvis, W.D., Caspase–9 regulation: an update. Apoptosis 9 (2004), 423–427.
44. Guerrero, A.D., Chen, M., Wang, J., Delineation of the caspase–9 signaling cascade. Apoptosis 13 (2008), 177–186.
45. Ding, W.X., Shen, H.M., Ong, C.N., Calpain activation after mitochondrial permeability transition in microcystin–induced cell death in rat hepatocytes. Biochem Biophys Res Commun 291 (2002), 321–331.
46. Dow, G.S., Hudson, T.H., Vahey, M., et al. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malar J, 2, 2003, 14.
47. Arrington, D.D., Van Vleet, T.R., Schnellmann, R.G., Calpain 10: a mitochondrial calpain and its role in calcium–induced mitochondrial dysfunction. Am J Physiol Cell Physiol 291 (2006), C1159–C1171.
48. Chen, M., Won, D.J., Krajewski, S., et al. Calpain and mitochondria in ischemia/reperfusion injury. J Biol Chem 277 (2002), 29181–29186.
49. Bartus, R.T., Elliott, P.J., Hayward, N.J., et al. Calpain as a novel target for treating acute neurodegenerative disorders. Neurol Res 17 (1995), 249–258.
50. Suzuki, T., Takamatsu, T., Oyamada, M., Expression of gap junction protein connexin43 in the adult rat cochlea: comparison with connexin26. J Histochem Cytochem 51 (2003), 903–912.
51. Vanhauwere, B., Maradit, H., Kerr, L., Post–marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg 58 (1998), 17–21.